Journal: Journal of clinical medicine

Article Title: Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma.

doi: 10.3390/jcm8122214

Figure Lengend Snippet: Figure 1. (A) The encapsulation efficiency of lapatinib within the liposomal formulation prepared with up to 2000 nmol lapatinib addition and the corresponding liposome size of the resultant liposomes. (B) Long-term stability of the liposomal lapatinib formulation prepared with 500 nmol lapatinib addition monitored by both z-average diameter and the respective polydispersity indices. (mean ± S.D., n = 3).

Article Snippet: A chloroform suspension of lapatinib ditosylate (925.46 g/mol, 10 mg/mL; Selleckchem, Radnor, PA, USA) was prepared, and 500 nmol of lapatinib ditosylate equivalent (46.3 μL) was added to the lipid mixture.

Techniques: Encapsulation, Formulation, Liposomes

Journal: Journal of clinical medicine

Article Title: Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma.

doi: 10.3390/jcm8122214

Figure Lengend Snippet: Figure 2. Live-cell imaging-based of protoporphyrin IX (PpIX) fluorescence within mitochondria and cytoplasm and the fraction between the two cellular locations as well as LD50 data when ALA and liposome-encapsulated lapatinib treatments were combined. (A) Percentage changes in PpIX production in the mitochondria following control (+HBEGF 5 ng/mL an epidermal growth factor receptor (EGFR) ligand commonly found in the brain for activation) and liposome-encapsulated lapatinib (500 nM) (+HBEGF) (* p < 0.05) (n = 3 biological replicates). (B) The fraction of PpIX in the mitochondria compared to the cytoplasm with and without lapatinib for all cell lines (* p < 0.05) (n = 3 biological replicates. (C) LD50 values of four glioma cell lines and one purported glioma cancer stem cell line (GS2) of PDT alone and PDT + Lapatinib, note LD50 of ALA, was chosen as a surrogate for PDT dose in these studies. A significant decrease in LD50 for the two EGFR positive cell lines U87 and U87vIII was defined by p < 0.05 (n = 3).

Article Snippet: A chloroform suspension of lapatinib ditosylate (925.46 g/mol, 10 mg/mL; Selleckchem, Radnor, PA, USA) was prepared, and 500 nmol of lapatinib ditosylate equivalent (46.3 μL) was added to the lipid mixture.

Techniques: Live Cell Imaging, Control, Activation Assay

Journal: Journal of clinical medicine

Article Title: Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma.

doi: 10.3390/jcm8122214

Figure Lengend Snippet: Figure 3. (A) MR images of central slices of five different U87 tumours prior to assignment to treatment groups including (a–e) contrast-enhanced T1w; and (f–j) T2w images (B) H&E staining of tumours at endpoint for each treatment groups. (C) Survival post-treatment of animals in each cohort (solid black line—control; solid grey line—lapatinib; short, broken line—photodynamic therapy (PDT) alone; broken line—PDT + lapatinib.

Article Snippet: A chloroform suspension of lapatinib ditosylate (925.46 g/mol, 10 mg/mL; Selleckchem, Radnor, PA, USA) was prepared, and 500 nmol of lapatinib ditosylate equivalent (46.3 μL) was added to the lipid mixture.

Techniques: Staining, Control